炎症性贫血的诊治进展

陈亚丽; 王芳; 黄玉敏; 姜中兴

doi:10.13201/j.issn.1004-2806.2022.11.001

炎症性贫血的诊治进展

- 郑州大学第一附属医院血液科(郑州，450000)

详细信息

作者简介:
姜中兴，博士，郑州大学第一附属医院血液内科主任，硕士生导师。担任中华医学会血液学分会委员，中华医学会血液学分会红细胞疾病学组副组长，中国医师协会血液学分会委员，中国抗癌协会血液肿瘤专委会委员，中国临床肿瘤学会抗白血病联盟委员，河南省医学会血液学分会主任委员，河南省医师协会血液科医师分会副会长，河南省实验血液学会主任委员，河南省抗癌协会血液病转化医学委员会主任委员。共发表论文100余篇，其中中华系列文章30篇，SCI文章30余篇，获科研成果2项，科研项目4项，专著4本，任《现代血液病诊断与治疗》副主编，《新编临床诊疗医学》主编，《诊断学》编委。在炎症性贫血规范化诊断和治疗方面经验丰富，多次在全国会议上做报告，致力于炎症性贫血的基础与临床研究

通讯作者: 姜中兴，E-mail：jiangzx313@126.com

中图分类号: R556

收稿日期: 2022-09-19

刊出日期: 2022-11-01

Progress in diagnosis and treatment of anemia of inflammation

More Information

Corresponding author: , E-mail: jiangzx313@126.com

Received Date: 19 September 2022

Publish Date: 01 November 2022

摘要

- 炎症性贫血 /
- 诊断 /
- 治疗
- anemia of inflammation /
- diagnosis /
- treatment

HTML全文

参考文献(23)

[1]	Weiss G, Ganz T, Goodnough LT. Anemia of inflammation[J]. Blood, 2019, 133(1): 40-50. doi: 10.1182/blood-2018-06-856500
[2]	Gangat N, Wolanskyj AP. Anemia of chronic disease[J]. Semin Hematol, 2013, 50: 232-238. doi: 10.1053/j.seminhematol.2013.06.006
[3]	张之南, 郝玉书. 血液病学[M]. 2版. 北京: 人民卫生出版社, 2011.
[4]	付蓉. 慢性病性贫血[M]//王建祥, 肖志坚, 沈志祥, 等. 邓家栋临床血液学. 2版. 上海: 上海科学技术出版社, 2020: 480-483.
[5]	陈苗, 李蓉生. 慢性病贫血[M]//沈悌, 赵永强. 血液病诊断及疗效标准. 4版. 北京: 科学出版社, 2018: 17-18.
[6]	Ganz T. Anemia of inflammation[J]. N Engl J Med, 2019, 381(12): 1148-1157. doi: 10.1056/NEJMra1804281
[7]	Goodnough LT, Murphy MF. Do liberal blood transfusions cause more harm than good?[J]. BMJ, 2014, 349, g6897. https://pubmed.ncbi.nlm.nih.gov/25501327/
[8]	Rizzo JD, Lichtin AE, Woof SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology[J]. J Clin Oncol, 2002, 20(19): 4083-4107. https://www.scholars.northwestern.edu/en/publications/use-of-epoetin-in-patients-with-cancer-evidence-based-clinical-pr-2
[9]	Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update[J]. J Clin Oncol, 2008, 26: 132-149. doi: 10.1200/JCO.2007.14.3396
[10]	Sasu BJ, Cooke Ks, Arvedson TL, et al. Anti-hepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of innammation-induced anemia[J]. Blood, 2010, 115(17): 3616-3624. doi: 10.1182/blood-2009-09-245977
[11]	Cooke K, Hinkle B, Salimi-Moosavi H, et al. A fully human anti-hepcidin antibody modulates 1ron metabolism in both mice and nonhuman primates[J]. Blood, 2013, 122(17): 3054-3061. doi: 10.1182/blood-2013-06-505792
[12]	Hohlbaum AM, Gille H, Trentmann S, et al. Sustained plasma hepcidin suppression and iron eleVation by Anticalin-derivedhepcldin antagonist in cynomoguls monkey[J]. Br J Pharmacol, 2018, 175(7): 1054-1065. doi: 10.1111/bph.14143
[13]	Schwoebel F, van Eijk LT, Zboralski D, et al. The effects of the anti-hepcidin spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys[J]. Blood, 2013, 121(12): 2311-2315. doi: 10.1182/blood-2012-09-456756
[14]	Van Eijk L, Swinkels D, John A, et al. Randomized double-blind placebo-controlled PK/PD study on the effects of a single intravenous dose of the anti-hepcidin Spiegelmer NOX-H94 on serum iron during experimental human endotoxemia[J]. Critical Care, 2013, 17(suppl 2): 352. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3642571/
[15]	Poli M, Girelli D, Campostrini N, et al. Heparin a potent inhibitor of hepcidin expression in vitor and in vivo[J]. Blood, 2011, 117(3): 997-1004.
[16]	Poli M, Asperti M, Naggi A, et al. Glycol-split nonanticoagulant heparins are lnhibitors of hepcidin expression in vitro and vivo[J]. Blood, 2014, 123(10): 1564-1573. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3945865/
[17]	Andriopoulos BJ, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism[J]. Nat Genet, 2009, 41(4): 482-487. doi: 10.1038/ng.335
[18]	Song SN, Tomosugi N, Kawabata H, et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody(tocilizumab)improve anemia of infllammation in muiticentric castleman disease[J]. Blood, 2010, 116(18): 3627-3634. doi: 10.1182/blood-2010-03-271791
[19]	Kurzrock R, Voorhees PM, Casper C, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease[J]. Clin Cancer Res, 2013, 19(13): 3659-3670.
[20]	Sheetz M, Barrington P, Callies S, et al. Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease[J]. Br J Clin Pharmacol, 85(5), 935-948.
[21]	Cao W, Fan W, Wang F, et al. GM-CSF impairs erythropoiesis by disrupting erythroblastic island formation via macrophages[J]. J Transl Med, 2022, 20: 11.
[22]	Chen N, Hao C, Liu BC, et al. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis[J]. N Engl J Med, 2019, 381(11): 1011-1022.
[23]	Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis[J]. N Engl J Med, 2019, 381(11): 1001-1010.